Laboratory Standards guidelines. For telithromycin, breakpoints of susceptibility and resistance were taken as Յ1 and Ն4 g/ml, respectively. Unless specifically mentioned, antibiotics were purchased from Sigma Chemical Co. (St. Louis, Mo.). In addition, the presence of the macrolide resistance determinants erm(B), mef(A), and erm(A) was detected by PCR. Genomic DNA was extracted by the alkaline lysis method (0.25% sodium dodecyl sulfate, 0.05 N NaOH). PCR was performed with a DNA thermal cycler (9600 GeneAmp PCR system; Perkin-Elmer, Zaventem, Belgium). The primers described previously for erm(B) and mef(A) give PCR products of 639 and 348 bp (9) , respectively, while a 590-bp product was obtained with the following primers for erm(A): 5Ј CCCGAA AAATACGCAAAATTTCAT 3Ј and 5Ј CCCTGTTTACCCA TTTATAAACG 3Ј (G. Cornaglia, personal communication). The PCR mix and cycling conditions for erm(B), and mef(A) were described previously (2) . For erm(A), each 50-l PCR mixture contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 0.01% gelatin, 200 M deoxynucleoside triphosphates (dNTPs), 1.5 mM MgCl 2 , 20 pmol of primers, 0.45 U of SuperTaq polymerase (Enzyme Technologies Ltd., United Kingdom), and 2 l of template DNA. The cycling conditions were an initial cycle of 5 min at 94°C; 35 cycles of 30 s of denaturation at 90°C, 60 s of annealing at 60°C, and 90 s of extension at 72°C; and finally 1 cycle of 5 min of elongation at 72°C. Positive controls used for erm(A), erm(B), and mef(A) were S. pyogenes strains UR1092, STP016, and STP046, respectively. Clonality was studied by pulsed field gel electrophoresis (PFGE) as well as emm typing as described previously (2, 5) .
All 16 bacitracin-resistant S. pyogenes strains demonstrated constitutive resistance to erythromycin and clindamycin, explained by the uniform presence of the erm(B) gene. Neither mef(A) nor erm(A) was detected in any isolate. For these 16 isolates, the MICs at which 90% of the isolates tested are inhibited of erythromycin, clindamycin, clarithromycin, azithromycin, telithromycin, tetracycline, penicillin, and ciprofloxacin were Ͼ512, Ͼ512, 512, Ͼ512, 8, 0.125, 0.01, and 0.5 g/ml, respectively. The PFGE clusters correlated completely with the emm typing results. Most interestingly, of the 16 isolates, 14 belonged to one PFGE cluster (10) and 1 particular emm type (emm28), and 2 isolates belonged to a distinct nonemm-typeable PFGE cluster (Fig. 1) . Of the 14 clonal isolates, 13 were isolated from patients residing in the southern Belgian provinces of Hainaut, Luxembourg, and Liège, while 1 isolate was from the northern province of Vlaams-Brabant.
So far, there has only been a single published report of a bacitracin-resistant S. pyogenes clone that was recovered from invasive infections (11) , indirectly suggesting that bacitracin resistance could be related to invasiveness. However, our findings of bacitracin-resistant S. pyogenes from pharyngitis patients suggest that there is no link between bacitracin resistance and invasiveness. Interestingly, both the earlier report (11) and this study show that the majority of the bacitracinresistant S. pyogenes isolates are clonal. Although no gene was ascribed to macrolide resistance in the previous study (11) , macrolide resistance in our clone was explained by the presence of erm(B). Moreover, the emm28 bacitracin-resistant clone was concentrated in southern Belgian provinces. We are currently investigating whether the presence of such strains could be related to the use of non-prescription-based bacitracin-containing throat lozenges. Also, efforts to elucidate the mechanism of bacitracin resistance in the emm28 clone are under way. Since bacitracin acts by preventing dephosphorylation and recycling of a lipid carrier (undecaprenol pyrophosphate), resistance to bacitracin, although not definitively characterized, is believed to result from an overproduction of undecaprenol kinase encoded by the bacA gene (reviewed in reference 1). Regardless of the precise reason for the resistance, a further search for bacitracin-resistant S. pyogenes isolates warrants that a preliminary screening for S. pyogenes should not rely on susceptibility to bacitracin.
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